Cargando…
Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. Th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853671/ https://www.ncbi.nlm.nih.gov/pubmed/24347984 http://dx.doi.org/10.4103/0976-500X.120963 |
_version_ | 1782294669189709824 |
---|---|
author | Giofrè, Chiara Scicchitano, Francesca Palleria, Caterina Mazzitello, Carmela Ciriaco, Miriam Gallelli, Luca Paletta, Laura Marrazzo, Giuseppina Leporini, Christian Ventrice, Pasquale Carbone, Claudia Saullo, Francesca Rende, Pierandrea Menniti, Michele Mumoli, Laura Chimirri, Serafina Patanè, Marinella Esposito, Stefania Cilurzo, Felisa Staltari, Orietta Russo, Emilio De Sarro, Giovambattista |
author_facet | Giofrè, Chiara Scicchitano, Francesca Palleria, Caterina Mazzitello, Carmela Ciriaco, Miriam Gallelli, Luca Paletta, Laura Marrazzo, Giuseppina Leporini, Christian Ventrice, Pasquale Carbone, Claudia Saullo, Francesca Rende, Pierandrea Menniti, Michele Mumoli, Laura Chimirri, Serafina Patanè, Marinella Esposito, Stefania Cilurzo, Felisa Staltari, Orietta Russo, Emilio De Sarro, Giovambattista |
author_sort | Giofrè, Chiara |
collection | PubMed |
description | INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. The Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) is financing several projects to increase reporting. In Calabria, a PV information center has been created in 2010. MATERIALS AND METHODS: We obtained data using the database of the National Health Information System AIFA relatively to Italy and Calabria in the year 2012. Descriptive statistics were performed to analyze the ADRs. RESULTS: A total number of 461 ADRs have been reported in the year 2012 with an increase of 234% compared with 2011 (138 reports). Hospital doctors are the main source of this reporting (51.62%). Sorafenib (Nexavar(®)), the combination of amoxicillin/clavulanic acid and ketoprofen represent the drugs most frequently reported causing adverse reactions. Adverse events in female patients (61.83%) were more frequently reported, whereas the age groups “41-65” (39.07%) and “over 65” (27.9%) were the most affected. CONCLUSIONS: Calabria has had a positive increase in the number of ADRs reported, although it has not yet reached the gold standard set by World Health Organization (about 600 reports), the data have shown that PV culture is making inroads in this region and that PV projects stimulating and increasing PV knowledge are needed. |
format | Online Article Text |
id | pubmed-3853671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38536712013-12-16 Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis Giofrè, Chiara Scicchitano, Francesca Palleria, Caterina Mazzitello, Carmela Ciriaco, Miriam Gallelli, Luca Paletta, Laura Marrazzo, Giuseppina Leporini, Christian Ventrice, Pasquale Carbone, Claudia Saullo, Francesca Rende, Pierandrea Menniti, Michele Mumoli, Laura Chimirri, Serafina Patanè, Marinella Esposito, Stefania Cilurzo, Felisa Staltari, Orietta Russo, Emilio De Sarro, Giovambattista J Pharmacol Pharmacother Research Article INTRODUCTION: Pharmacovigilance (PV) is designed to monitor drugs continuously after their commercialization, assessing and improving their safety profile. The main objective is to increase the spontaneous reporting of adverse drug reactions (ADRs), in order to have a wide variety of information. The Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) is financing several projects to increase reporting. In Calabria, a PV information center has been created in 2010. MATERIALS AND METHODS: We obtained data using the database of the National Health Information System AIFA relatively to Italy and Calabria in the year 2012. Descriptive statistics were performed to analyze the ADRs. RESULTS: A total number of 461 ADRs have been reported in the year 2012 with an increase of 234% compared with 2011 (138 reports). Hospital doctors are the main source of this reporting (51.62%). Sorafenib (Nexavar(®)), the combination of amoxicillin/clavulanic acid and ketoprofen represent the drugs most frequently reported causing adverse reactions. Adverse events in female patients (61.83%) were more frequently reported, whereas the age groups “41-65” (39.07%) and “over 65” (27.9%) were the most affected. CONCLUSIONS: Calabria has had a positive increase in the number of ADRs reported, although it has not yet reached the gold standard set by World Health Organization (about 600 reports), the data have shown that PV culture is making inroads in this region and that PV projects stimulating and increasing PV knowledge are needed. Medknow Publications & Media Pvt Ltd 2013-12 /pmc/articles/PMC3853671/ /pubmed/24347984 http://dx.doi.org/10.4103/0976-500X.120963 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Giofrè, Chiara Scicchitano, Francesca Palleria, Caterina Mazzitello, Carmela Ciriaco, Miriam Gallelli, Luca Paletta, Laura Marrazzo, Giuseppina Leporini, Christian Ventrice, Pasquale Carbone, Claudia Saullo, Francesca Rende, Pierandrea Menniti, Michele Mumoli, Laura Chimirri, Serafina Patanè, Marinella Esposito, Stefania Cilurzo, Felisa Staltari, Orietta Russo, Emilio De Sarro, Giovambattista Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title | Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title_full | Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title_fullStr | Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title_full_unstemmed | Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title_short | Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis |
title_sort | pharmacovigilance and drug safety in calabria (italy): 2012 adverse events analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853671/ https://www.ncbi.nlm.nih.gov/pubmed/24347984 http://dx.doi.org/10.4103/0976-500X.120963 |
work_keys_str_mv | AT giofrechiara pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT scicchitanofrancesca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT palleriacaterina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT mazzitellocarmela pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT ciriacomiriam pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT gallelliluca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT palettalaura pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT marrazzogiuseppina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT leporinichristian pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT ventricepasquale pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT carboneclaudia pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT saullofrancesca pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT rendepierandrea pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT mennitimichele pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT mumolilaura pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT chimirriserafina pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT patanemarinella pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT espositostefania pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT cilurzofelisa pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT staltariorietta pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT russoemilio pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT desarrogiovambattista pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis AT pharmacovigilanceanddrugsafetyincalabriaitaly2012adverseeventsanalysis |